Sanifit and Mitelos make available to Doctors and patients a new alternative in osteoporosis
Sanifit and Mitelos have successfully concluded the development, registration and industrial scaled up of SNF671, a breakthrough patent protected dietary supplement to prevent osteoporosis within postmenopausal women, which was originated at the Laboratory of Renal Lithiasis Research of the University of the Balearic Islands.
SNF671 has proven efficacy both in in vitro and in vivo models, as well as in 3 epidemiology clinical studies, where the exposure to SNF671 correlates with increased bone mineral density and reduced bone mass loss.
SNF671 is of special relevance after the publication in a recent editorial in the British Medical Journal that there is no clinical trial evidence that increasing calcium intake from dietary sources prevents fractures. Quite to the contrary, patients will not benefit from increasing their intake of calcium and will be exposed instead to a higher risk of adverse events such as constipation, cardiovascular events, kidney stones, or admission for acute gastrointestinal symptoms.
Therefore, SNF671 is a new alternative to calcium supplements that comes at the right time, when such supplements are being questioned.
Sanifit and Mitelos are actively seeking licensees and some agreements are in advance stage of negotiation.
Sanifit is a clinical stage biopharmaceutical company focused on the development of medicines to treat calcium metabolism and calcification disorders. The company was founded in 2007 as a spin-off of the University of the Balearic Islands. After a recent series C funding round of $41.3M (€36.6M), Sanifit will start a phase IIb study in End Stage Renal Disease population undergoing haemodialysis and extend the orphan program in calciphylaxis into phase II/III clinical trials. For more information please visit www.sanifit.com
Mitelos is a private and independent health products company and business development services provider located in the area of Barcelona, Catalonia, Spain. Mitelos develops, registers and licenses its own products in addition to help its clients achieve their growth objectives.
For more information and licensing deals, contact: